SM
RVPH

Sabby Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Sabby Management’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,496
Closed -$72.2K – 57
2025
Q2 		$64.8K Buy
+8,496
New +$132K 0.12% 35
2024
Q3 		– Sell
-11,850
Closed -$263K – 57
2024
Q2 		$303K Buy
+11,850
New +$539K 0.2% 15
2023
Q4 		– Sell
-2,230
Closed -$218K – 83
2023
Q3 		$218K Buy
+2,230
New +$208K 0.16% 36
2023
Q2 		– Sell
-1,431
Closed -$181K – 107
2023
Q1 		$120K Sell
1,431
-294
-17% -$25.7K 0.1% 54
2022
Q4 		$147K Buy
1,725
+225
+15% +$17.2K 0.13% 57
2022
Q3 		$48K Buy
+1,500
New +$41.4K 0.06% 90
2021
Q2 		– Sell
-20,922
Closed -$2.4M – 185
2021
Q1 		$2.4M Buy
20,922
+3,007
+17% +$502K 0.47% 42
2020
Q4 		$3.13M Buy
+17,915
New +$3.63M 0.6% 29

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sabby Management's RVPH Position: Q3 2025 in Review

Sabby Management sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 8,496 shares — an estimated $72.2K sold.

Sabby Management first reported a position in RVPH in Q4 2020 and held it in 8 quarters. The position peaked at $3.13M in Q4 2020. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Sabby Management reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Sabby Management sold 8,496 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $72.2K.
  • Sabby Management first reported a position in REVIVA PHARMA HLDGS INC in Q4 2020 and held it in 8 quarters.
  • Sabby Management's REVIVA PHARMA HLDGS INC position peaked at $3.13M in Q4 2020.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Sabby Management's 13F filing for Q3 2025, filed 14 Nov 2025.